» Articles » PMID: 33269553

Comparison of High-flow Oxygenation with Noninvasive Ventilation in COPD Exacerbation: A Crossover Clinical Trial

Overview
Journal Clin Respir J
Specialty Pulmonary Medicine
Date 2020 Dec 3
PMID 33269553
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To compare the therapeutic effects of high-flow-oxygen-Therapy (HFT) and noninvasive-ventilation (NIV) for stabilizing chronic obstructive pulmonary disease during exacerbation.

Methods: In this randomized clinical trial at Masih-Daneshvari hospital, between July 2019 and Oct 2019, 30 exacerbated-COPD-patient with PaCO 64.58 ± 11.61 mm Hg, Respiratory Rate 24.43 ± 2.75, and PH 7.31 ± 0.02 were divided into two groups, N = 15. By a simple randomized allocation, patients receive either NIV or HFT for 1 hour, and following a washout period of 30 minutes, they switched to the other treatment option. Arterial Blood Gas Parameters, as well as Respiratory Rate (RR), Dyspnea Score, Heart Rate (HR), and Oxygen Saturation (SO ), were compared before and after the intervention and between groups.

Results: Baseline patient characteristics were similar in the two groups. Pre and post-analysis revealed that in both groups, all improved significantly. After the first period, there was no difference in all parameters between groups except for SO which was significantly higher in HFT (%92.1 ± 1) than that of NIV (%89 ± 1), P = .001. Likewise, following the washout period, patients in HFT and NIV had a dyspnea score of 1.93 ± 0.7 and 2.73 ± 0.9, respectively, P = .01. No carryover-effect and was observed but the period effect was significant for some outcomes. A significant improvement in SO and HR was observed by HFT according to treatment effect by combining two periods' results. During the study, no side effects were reported.

Conclusion: In this short-term study HFT appears feasible for patients with COPD exacerbation to reduce dyspnea score and improve respiratory distress.

Citing Articles

High-Flow Nasal Oxygen in Patients with Acute Hypercapnic Respiratory Failure: A Narrative Review of the Physiological Rationale and Clinical Evidence.

Pintaudi G, Cutuli S, Rosa T, Michi T, Cardu A, Bongiovanni F J Clin Med. 2024; 13(21).

PMID: 39518490 PMC: 11546100. DOI: 10.3390/jcm13216350.


The Use of High-Flow Nasal Cannula in the Emergency Department and a Comparison of Its Efficacy With Noninvasive Ventilation.

Shinde V, Mavudelli S Cureus. 2024; 16(7):e65709.

PMID: 39211709 PMC: 11361467. DOI: 10.7759/cureus.65709.


High flow nasal cannula oxygen therapy versus non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease with acute-moderate hypercapnic respiratory failure: a randomized controlled non-inferiority trial.

Tan D, Wang B, Cao P, Wang Y, Sun J, Geng P Crit Care. 2024; 28(1):250.

PMID: 39026242 PMC: 11264824. DOI: 10.1186/s13054-024-05040-9.


High flow nasal cannula versus noninvasive ventilation in the treatment of acute hypercapnic respiratory failure: A systematic review and meta-analysis.

Fahey A, OConnell M, Cornally N, Saab M Clin Respir J. 2023; 17(11):1091-1102.

PMID: 37700578 PMC: 10632084. DOI: 10.1111/crj.13695.


Comparison of High Flow Nasal Therapy with Non-Invasive Ventilation and Conventional Oxygen Therapy for Acute Hypercapnic Respiratory Failure: A Meta-Analysis of Randomized Controlled Trials.

Xu C, Yang F, Wang Q, Gao W Int J Chron Obstruct Pulmon Dis. 2023; 18:955-973.

PMID: 37251703 PMC: 10215944. DOI: 10.2147/COPD.S410958.